Louisiana State Employees Retirement System Sells 800 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Louisiana State Employees Retirement System trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,700 shares of the medical equipment provider’s stock after selling 800 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Zimmer Biomet were worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC raised its holdings in Zimmer Biomet by 3,043.1% in the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after purchasing an additional 1,552 shares during the period. NBC Securities Inc. acquired a new stake in Zimmer Biomet in the third quarter worth $105,000. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Zimmer Biomet by 1.5% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock worth $2,400,000 after purchasing an additional 337 shares during the period. Blue Trust Inc. raised its holdings in Zimmer Biomet by 165.3% in the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after purchasing an additional 1,071 shares during the period. Finally, Border to Coast Pensions Partnership Ltd increased its position in shares of Zimmer Biomet by 4.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock worth $16,711,000 after acquiring an additional 6,623 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Up 0.6 %

ZBH opened at $100.52 on Tuesday. The company’s 50 day moving average is $106.34 and its 200-day moving average is $107.67. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. The company has a market cap of $20.01 billion, a P/E ratio of 22.59, a PEG ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm posted $2.20 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of several research reports. Truist Financial reissued a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Barclays decreased their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Wells Fargo & Company lifted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.